AUS
NZ
UK
CA
USA
IND
Highlights
- Orthocell Ltd (ASX:OCC) expands Remplir™ into global markets, backed by strong sales growth.
- The US market opportunity valued at ~US$1.6 billion per year.
- Anticipated FDA clearance for Remplir™ set for March/April 2025.
Orthocell Ltd (ASX:OCC), a leading regenerative medicine company, is poised to significantly expand its global footprint after witnessing remarkable sales traction for its innovative nerve repair product, Remplir™. Following successful launches in Australia, New Zealand, and Singapore, where sales have reached record highs, Orthocell is accelerating its international strategy, targeting additional markets throughout 2025, including the USA, Canada, Thailand, United Kingdom, European Union, and Brazil.
The company’s strong performance in its existing markets is a clear indication of Remplir’s potential. Remplir, a collagen wrap designed to assist nerve repair surgeries, is already proving to be an invaluable tool for approximately 160 surgeons, improving outcomes in procedures ranging from facial nerve repairs to surgeries on upper and lower limb nerves. The unique properties of Remplir, which promote optimal healing and reduce the need for extensive suturing, have helped Orthocell gain significant traction since its Australian launch in November 2022.
A key milestone on the company’s expansion journey is the imminent clearance for Remplir in the US market, the largest global market for nerve repair, worth an estimated US$1.6 billion annually. Approval is expected in March or April 2025, with commercialization set to begin shortly thereafter. With seasoned US-based executives now leading the charge, Orthocell is well-positioned to tap into this lucrative market.
Orthocell’s growth plans are not limited to the US. The company is progressing with regulatory submissions for markets across Canada, Thailand, the UK, EU, and Brazil. These key territories, expected to go live in the coming years, represent a substantial revenue opportunity, raising Orthocell’s addressable market to an impressive US$3.2 billion. Additionally, the company is exploring opportunities in other ASEAN markets such as Taiwan, Vietnam, Indonesia, and the Philippines, as well as other Latin American markets.
Orthocell’s strategic expansion is underpinned by a solid balance sheet, with approximately $33 million in cash reserves, positioning the company well for long-term growth. With over 1.8 million potential peripheral nerve repairs across its markets, Orthocell is targeting a 20% market share of this sizable global market.
With its international growth on track, Orthocell Ltd looks set to continue its impressive trajectory, making substantial headway in the rapidly expanding regenerative medicine space.
